

October 1-3, 2024 | Boston, MA  
www.ipsc-therapies-summit.com

SAVE UP TO  
\$850 WHEN YOU  
REGISTER BEFORE  
JULY 12

4th Annual  
**iPSC Drug Development &  
Manufacturing Summit**  
Driving Proof of Concept & Scalable Manufacturing

**Improving Gene Engineering,  
Enhancing Potency &  
Streamlining Manufacturing  
to Accelerate Stable, Safe &  
Clinically Validated iPSC-Derived  
Cell Therapies to Market**

**Expert Speakers Include:**



Howard Federoff  
Chief Medical Officer  
& Scientific Co-  
Founder  
Kenai Therapeutics



Wei Li  
Chief Scientific  
Officer  
Cytovia  
Therapeutics



Matt Angel  
Chief Executive  
Officer,  
Factor Bioscience



Annelise Bennaceur  
Chief Scientific  
Officer  
iPSirius



Joseph Wu  
Professor & Director  
Stanford  
Cardiovascular  
Institute



Laura Koivusalo  
Chief Executive  
Officer  
StemSight

+1 617 455 4188 @ info@hansonwade.com www.ipsc-therapies-summit.com

iPSC-Derived Cell Therapies: Pioneering the Future of Cell Therapy



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

# Welcome to the 4th iPSC Drug Development & Manufacturing Summit

To our dedicated iPSC Community,

Positive preclinical data hit the headlines following ASCGT recently, with **Century Therapeutics** and **Fate Therapeutics** revealing approaches which could lead to potential clinical benefit for autoimmune and oncology.

And with the recent funding successes of **Kenai Therapeutics** and **Shinobi Therapeutics** - the iPSC community knows that once the first truly positive proof of concept data demonstrates persistency, safety and clinical efficacy is shown – another wave of investment and excitement is set to be on its way.

As the field rush closer to the clinic, there is undoubtedly a need to unite to share learnings and collaborate to propel the industry forward. This is why we're excited to introduce the **4th Annual iPSC Drug Development & Manufacturing Summit!**

This summit is your one-stop shop for everything iPSC. As the longest-running iPSC-focused conference, this platform will bring you the latest advancements across the entire spectrum from R&D to manufacturing and analytical development. Here, you'll gain the knowledge and connections required to stay ahead of the curve over these important next few years.

Join leading industry pioneers like **AstraZeneca**, **Aspen Neuroscience**, **Cytovia** and **Shoreline Bio** as they tackle critical challenges like optimizing differentiation, improving pre-clinical safety, and implementing automation technologies into their manufacturing processes with the goal of producing safer and more accessible iPSC therapies for treatment of a vast variety of disease indications.

If you are dedicated to the clinical development of iPSC therapies, this is the one event made for you! Don't miss your only chance to connect with the iPSC community and be at the forefront of new industry updates. Assemble your discovery, translational, manufacturing, and analytical teams learn how to streamline research with improved preclinical models, explore scalable manufacturing processes to reduce costs, and apply these learnings to your pipeline, including novel disease indications like autoimmune conditions and solid tumors.



Aidan Steele

Program Director – 4th iPSC Drug Development & Manufacturing Summit

## What our past attendees have to say:

“The 2023 summit provided field leaders an opportunity to share cutting-edge preclinical technical advances/challenges and learn the landscape of current cell therapies for oncology and regenerative medicine”

**Director, MSAT, Astellas, Past Attendee**

“The session chairs were excellent in moderating discussion panels and Q&As”

**Head of CMC, Century Therapeutics, Past Attendees**

## KEY BENEFITS OF ATTENDING



Our **brand-new two-track structure** allows for you to engage with super-relevant presentations and a tailored speaker faculty speaking on your most pressing challenges whether they be preclinical research or manufacturing and analytical development



Discover the breakthrough work of **Kenai Therapeutics**, as **Howard Federoff** explains how their innovative iPSC technologies aim to combat Parkinson's disease following their latest funding round



Reinvigorate your preclinical pipeline with learnings from iPSC drug developers who are innovating in entirely new indications with presentations from **Tome Biosciences**, **Thymune** and **Stemsight**



Gain insights into the future of iPSC manufacturing, as leaders from **Aspen Neuroscience** and the **NIST** discuss integrating AI and automation into their processes to improve product quality and cut costs



Optimize your iPSC differentiation protocols to improve your product's efficacy with insights from **Century Therapeutics** and **Stemson Therapeutics**

# Your Expert Speakers

An Annual  
iPSC Drug Development &  
Manufacturing Summit

October 1-3, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**Will Ansari**  
Associate Director,  
Technology Development  
**Aspen Neuroscience**



**Rajneesh Jha**  
Associate Principal  
Scientist  
**AstraZeneca**



**Zhu Pirot**  
Director & Technical  
Leader Platform CGT  
Analytical  
**Bayer**



**Matt Moran**  
Senior Associate  
Development Engineer  
**Bayer**



**Dhruv Sareen**  
Executive Director &  
Associate Professor  
**Cedars-Sinai Medical  
Center**



**Michael Naso**  
Vice President  
**Century Therapeutics**



**Jason Mills**  
Director, Process  
Development  
**Century Therapeutics**



**Wei Li**  
Chief Scientific Officer  
**Cytovia Therapeutics**



**Matt Angel**  
Chief Executive Officer,  
**Factor Bioscience**



**Bruna Paulsen**  
Director, Manufacturing &  
Quality Control  
**Gameto**



**Takehiko Kaneko**  
Chief Medical Officer,  
Head of Research &  
Development  
**Heartseed**



**Allen Feng**  
Founder & Chief Scientific  
Officer  
**HebeCell**



**Annelise Bennaceur-  
Griscelli**  
Co-Founder  
**iPSirius**



**Ali Turhan**  
Chief Medical Officer  
**iPSIRIUS**



**Howard Federoff**  
Chief Medical Officer &  
Scientific Co-Founder  
**Kenai Therapeutics**



**Harshyaa Makhija**  
Postdoctoral Fellow  
**Nanyang Technological  
University**



**Anne Plant**  
Fellow Chief, Biosystems  
& Biomaterials Division  
**National Institute of  
Standards & Technology**



**Sherry Hikita**  
Project Director, Cell  
Therapy R&D  
**Novo Nordisk**



**David Rodgers**  
Senior Director,  
Macrophage Cell Therapy  
**Shoreline Biosciences**



**Joseph Wu**  
Professor & Director  
**Stanford Cardiovascular  
Institute**



**Laura Koivusalo**  
Chief Executive Officer &  
Founder  
**StemSight**




**Kevin D'Amour**  
Chief Scientific Officer  
**Stemson Therapeutics**



**Nicholas Wisniewski**  
Vice President of Data  
Science & Bioinformatics  
**Stemson Therapeutics**



**Chris Barkey**  
Chief Executive Officer  
**Swissfinity**



**Leonardo Velazco Cruz**  
Senior Scientist  
**Thymune Therapeutics**



**Chong Luo**  
Director, Cell Therapy  
**Tome Biosciences**



**Dongsheng Guo**  
Instructor  
**UMass Chan Medical  
School**

# Pre-Conference Workshop Day Tuesday October 1, 2024

Our workshops offer a unique opportunity to look more deeply into specialized areas of iPSC research and manufacturing, led by experts in the field. Engage with niche areas of iPSC development, gaining detailed insights during deep-dive sessions involving both presentations, roundtable discussions and dedicated networking time. Connect with peers and professionals who share an interest in your specific field of work. Acquire specialized information and practical takeaways that may not be touched upon in the main conference content.

## Check-In, Coffee & Light Breakfast

8.00

## Workshop A

9.00

### Demystifying iPSC Fundamentals by Evaluating Cutting-Edge Research into Reprogramming & Characterization

This workshop is essential for researchers and professionals who are looking to keep up to date on the cutting-edge applications and innovations currently ongoing in preclinical and academic research organizations. Be sure to attend to enhance your understanding of iPSC biology and how these latest discoveries can be applied in your own work.

- This interactive session will showcase recent academic breakthroughs and ongoing research efforts in the field of iPSCs, highlighting their potential for regenerative medicine and disease modeling
- Delving deeper into current research trends and the latest academic innovations for iPSC research

#### Workshop Leaders



**Rajneesh Jha**  
Associate Principal  
Scientist  
AstraZeneca

## Lunch Break

12.00

## Workshop B

1.00

### Working Towards Standardized Manufacturing Processes to Unite the iPSC Community & Ultimately Reduce Costs

This workshop is vital for professionals aiming to streamline iPSC production and reduce associated costs. This session will address the need for standardized manufacturing practices to expedite development timelines and enhance collaboration within the iPSC community, with the goal of accelerating the commercialization of iPSC technologies.

- Establishing common ground in iPSC manufacturing to expedite development timelines and reduce costs
- Understanding requirements for GMP manufacturing of iPSC technologies
- Streamlining iPSC manufacturing processes to reduce production time and accelerate commercialization

#### Workshop Leaders



**Allen Feng**  
Founder & Chief  
Scientific Officer  
HebeCell

## End of Workshop Day

4.00

# Conference Day One

## Wednesday October 2, 2024



8.00 Check-In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

### Uniting iPSC Innovators to Evaluate the iPSC Landscape & Identify Routes to Growth

#### 9.00 Industry Leaders' Fireside Chat: Highlights & Hurdles from the Past Year

An interactive panel discussion from the industry leaders of the field to set the scene on the iPSC therapy space. Ask your questions live to understand the expert's thoughts on key topics including:

- Highlighting and celebrating the big wins for iPSC community like recent start-ups and progress being made by US & Asian biopharma
- Considering the challenges facing iPSC research including safety, current regulatory frameworks and routes to clinic



**Kevin D'Amour**  
Chief Scientific Officer  
Stemson Therapeutics



**Wei Li**  
Chief Scientific Officer  
Cytovia Therapeutics



**Howard Federoff**  
Chief Medical Officer & Scientific Co-Founder  
Kenai Therapeutics



**Joseph Wu**  
Professor & Director  
Stanford  
Cardiovascular  
Institute

#### 9.30 Unlocking Drug Discovery with the World's Largest iPSC Biobank

- Leveraging a unique resource of 2,000 patient-derived iPSC lines, to understand the links between genetics and drug response
- This biobank empowers large-scale drug screening and paves the way for faster identification of effective and personalized therapies
- By integrating automation and innovative technologies, we aim to unlock the full potential of iPSCs and revolutionize drug development



**Wei Li**  
Chief Scientific Officer  
Cytovia Therapeutics

#### 10.00 Optimizing the Differentiation of iPSC Therapies to Enable Large-Scale Manufacturing & Clinical Applications

- Investigating the mechanisms by which differentiated Cytovia's iNK cells exert their anti-tumor effects
- Demonstrating the complete maturation and potent anti-tumor activity of differentiated iNK cells for optimal efficacy



#### 10.30 Morning Refreshment Break & Speed Networking

As the iPSC community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don't forget to enjoy some refreshments before we split off into 2 tracks: **Research & Development** and **Manufacturing & Analytical Development**

### Research & Development

### Manufacturing & Analytical Development

#### Improving Preclinical Models to Streamline Transition to the Clinic

##### 12.00 Overcoming Weaknesses of Current *In Vitro* Models using Novel *In Vivo* Approaches

- Investigating key factors contributing to tumorigenesis in iPSCs to identify areas in need of greater attention during cell reprogramming and differentiation
- Employing *in vitro* and *in vivo* models to assess the tumorigenic potential of iPSC-derived cells, facilitating the selection of safer cell lines for therapeutic development
- Mitigating tumorigenicity risks throughout preclinical development, ultimately enhancing the safety and efficacy of iPSC-based therapies



**Kevin D'Amour**  
Chief Scientific Officer  
Stemson Therapeutics

#### Revolutionizing iPSC Manufacturing through Automation & Artificial Intelligence

##### 12.00 Accelerating iPSC Differentiation with Novel Automation Technologies to Streamline Manufacturing Processes

- Exploring how AI can optimize differentiation protocols to reduce timelines and improve cell yield
- Examining the implementation of automated workflows for iPSC differentiation, promoting consistency and efficiency
- Highlighting how machine learning can be used to predict and control differentiation processes, leading to more targeted cell production



**Will Ansari**  
Associate Director, Technology  
Development  
Aspen Neuroscience

# Conference Day One

## Wednesday October 2, 2024


### 12.30 Approaching Hard-to-Model Cell Types to Improve Preclinical Research in New Disease Areas

- Implementing methods to culture and manipulate previously inaccessible cell types, enabling the study of their role in disease
- Integrating microfluidic and organoid technologies to create complex microenvironments, enhancing the translation of preclinical findings to clinical applications
- Understanding how academic approaches to preclinical modeling can be expanded and applied to industry-scale

**Dongsheng Guo**  
Instructor  
UMass Chan Medical School

### 12.30 Harnessing AI & Data Science to Increase the Role of iPSCs in Regenerative Medicine

- Leveraging AI and data science workflows developed at NIST to optimize differentiation protocols for iPSCs, reducing timelines and improving cell yield
- Examining the implementation of automated workflows for iPSC differentiation, integrating AI-powered data analysis for enhanced consistency and efficiency
- Highlighting how data science and machine learning can be used to predict and control differentiation processes, leading to more targeted cell production

**Anne Plant**  
Fellow Chief, Biosystems & Biomaterials Division  
National Institute of Standards & Technology




### 1.00 Lunch Refreshment

### Evaluating Novel Approaches to Improving Efficiency of iPSC Differentiation to Improve Yields & Product Efficacy

#### 2.00 Optimizing Differentiation for Therapeutic Applications of iPSC-Derived Cell Therapies


- Uncovering the mechanisms by which differentiated iPSCs exert their therapeutic effects
- Enabling the development of modular differentiation protocols for targeted cell production with defined functionalities
- Demonstrating the complete and functional maturation of differentiated iPSCs for therapeutic use

**Michael Naso**  
Vice President  
Century Therapeutics

### Enhancing iPSC Manufacturing Upscaling to Enable Truly Accessible Therapeutic Pathways


#### 2.00 Highlighting Innovations in Bioreactor Technologies to Enable Scale-Up of Manufacturing Processes

- Spotlighting novel bioreactor designs specifically suited for efficient and scalable iPSC production
- Strategizing how bioreactor innovations can be used to optimize oxygenation, nutrient delivery, and other critical culture conditions for large-scale iPSC expansion
- Highlighting the potential for integrating novel bioreactors with automation technologies for streamlined iPSC manufacturing processes

**Matt Moran**  
Senior Associate Development Engineer  
Bayer

### 2.30 Harnessing AI/ML & Organoids to Optimizing a Unique Cell Therapy for Hair Loss

- Understanding the fundamentals of how AI & ML can be integrated into existing preclinical workflows
- Leveraging the autonomous benefits of AI technologies to enhance the efficacy of iPSC therapeutics
- How can we apply these new learnings to Stemson's cell therapy approach for hair regeneration?

**Nicholas Wisniewski**  
Vice President of Data Science & Bioinformatics  
Stemson Therapeutics

### 2.30 Derisking Large Scale iPSC Manufacturing by Decreasing Costs

- Reducing the cost of goods associated with iPSC manufacturing while maintaining quality and scalability
- Highlighting the importance of process optimization for minimizing waste and maximizing cell yield during large-scale iPSC production
- Understanding how scaling up iPSC manufacturing can lead to cost reductions through efficient resource utilization

**Jason Mills**  
Director, Process Development  
Century Therapeutics



### 3.00 Afternoon Refreshment Break & Networking

# Conference Day One

## Wednesday October 2, 2024

### Overcoming Regulatory & Protocol Challenges for iPSC Therapies from Bench to Clinic



**Takehiko Kaneko**  
Chief Medical Officer,  
Head of Research &  
Development  
**Heartseed**

#### 4.00 Translating Differentiation Protocols from Research to Industry

- Driving scale-up of research-grade differentiation protocols for robust and cost-effective iPSC manufacturing
- Optimizing differentiation processes for consistent production of high-quality differentiated iPSCs
- Exploring the integration of optimized differentiation protocols with automated and closed manufacturing systems for streamlined cell therapy production



**Matt Angel**  
Chief Executive Officer  
**Factor Biosciences**

#### 4.30 Regulatory Roundtables: Case Studies & Lessons Learned

Join a dynamic roundtable discussion featuring experts who have successfully navigated the regulatory landscape for iPSC therapies. This session will present real-world case studies exploring the challenges and solutions encountered during various stages of development, from preclinical studies to clinical trials. Attendees will have the opportunity to ask questions and gain valuable insights into navigating the regulatory pathways for iPSC-based cell therapies.

#### 5.00 Chair's Closing Remarks & End of Day Conference One

▀▀ There was a strong presence and innovative portfolios of several leading players in the domain of CAR-T cell therapies ▀▀

**Senior Scientist, Orizuru, Past Attendee**

▀▀ The session chairs were excellent in moderating discussion panels and Q&As ▀▀

**Head of CMC, Century Therapeutics, Past Attendee**

# Conference Day Two

## Thursday October 3, 2024



8.00 Check-In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

### Targeting Novel Indications & Applications for iPSC Therapeutics to Meet Patient Need



**Howard Federoff**  
Chief Medical Officer &  
Scientific Co-Founder  
**Kenai Therapeutics**

9.00 **Unlocking the Potential of iPSC Therapies for Parkinson's Disease**

- Investigating the expanding application of iPSC technology to create cell-based therapies for Parkinson's disease
- Highlighting the importance of developing reliable preclinical models to assess the safety and effectiveness of iPSC therapies in Parkinson's disease



**Chong Luo**  
Director, Cell Therapy  
**Tome Biosciences**

9.30 **Tailoring iPSC Therapies for Autoimmune Diseases to Address Unmet Patient Needs**

- Delving into the potential of using patient-derived iPSCs to create targeted cell therapies for specific autoimmune diseases
- Regulating the immune system and achieving disease remission in autoimmune conditions
- Developing rigorous preclinical models that accurately reflect the human immune response to assess the safety and effectiveness of iPSC therapies for autoimmune diseases

10.00 **Panel Discussion: Unlocking the Potential of iPSC Therapies for Non-Cancer Indications**

- Promising new applications for iPSC therapies, highlighting specific examples beyond heart failure, and focusing on areas of significant unmet medical need
- Examining the unique challenges and opportunities associated with developing iPSC therapies for non-cancer diseases, exploring the path from basic research to patient care



**David Rodgers**  
Senior Director, Macrophage Cell Therapy  
**Shoreline Biosciences**



**Laura Koivusalo**  
Chief Executive Officer & Founder  
**StemSight**



**Leonardo Velazco Cruz**  
Senior Scientist  
**Thymune Therapeutics**



11.00 **Morning Refreshment Break & Poster Session**

As the iPSC community is reunited, this poster session will allow attendees to share research that will not be presented in speaking sessions. Don't forget to enjoy some refreshments before we split off into 2 tracks: **Research & Development** and **Manufacturing & Analytical Development**

#### Research & Development

**Novel Approaches to Advanced Gene Editing of iPSCs to Enable Improved Control & Safety**

12.00 **Streamlining Gene Editing for iPSC Therapies to Reduce Off-Target Edits & Reduce Delays**

- Exploring the latest gene editing technologies like mRNA reprogramming for precise modification of iPSCs in preclinical research
- Streamlining gene editing workflows, minimizing unintended edits, for faster development of iPSC therapies



**Harshyaa Makhija**  
Postdoctoral Fellow  
**Nanyang Technological University**

#### Manufacturing & Analytical Development

**Enhancing Quality & Potency Assay Development for iPSC Processes**

12.00 **Enhancing Assay Development & Cell Bank Characterization for iPSC Manufacturing**

- Streamlining iPSC manufacturing with robust quality control to ensure consistent, high-quality iPSCs for efficient and reliable production
- Unlocking therapeutic potential of iPSCs by linking cellular traits to efficacy for targeted therapies and improved patient outcomes



**Dhruv Sareen**  
Executive Director & Associate Professor  
**Cedars-Sinai Medical Center**



# Conference Day Two

## Thursday October 3, 2024

### 12.30 Ensuring Safety in Gene-Edited iPSC Therapies to Accelerate Development of Next-Generation Treatments

- Focusing on methods for maintaining genomic stability and minimizing mosaicism after gene editing in iPSCs, promoting safety
- Developing new genomic stability testing methods to ensure the safety of iPSC-derived cell therapies



**Matt Angel**  
Chief Executive Officer  
Factor Biosciences

### 12.30 Developing Standardized & Scalable Potency Assays to Ensure Effective Quality Control of iPSC Therapeutics

- Elevating the importance of comprehensive quality control procedures throughout the iPSC manufacturing process to ensure consistent product quality and safety
- Exploring ongoing research into identifying cellular and functional characteristics within iPSC-derived cells that correlate with therapeutic efficacy, aiding in dose selection and improving overall product quality



**Bruna Paulsen**  
Director, Manufacturing & Quality Control  
Gameto



### 1.00 Lunch Refreshment

### Safety Considerations for Developing iPSC-Derived Cell Therapies for Treating Solid Tumor

#### 2.00 Revolutionizing the Treatment of Solid Tumors Utilizing iPSCs to Unlock Treatments for a New Frontier of Oncology

- Engineering iPSCs designed to target and treat solid tumors as a promising new approach to cancer treatment
- Utilizing iPSCs to address the three major hurdles associated with cancer treatment: metastasis, treatment resistance, and relapse
- Combating the tumor microenvironment using iPSCs to stimulate a stronger immune response



**Annelise Bennaceur**  
Chief Scientific Officer  
iPSirius

### Tailoring Logistics & Storage for Successful iPSC Therapies

#### 2.00 Optimizing Logistics & Cryopreservation of iPSCs to Streamline Product Delivery

- Examining best practices for selecting starting materials, such as donor tissue or reprogramming methods, to ensure the safety and efficacy of iPSC therapies in preclinical research
- Evolving GMP requirements for starting materials used in iPSC therapy development, including considerations for media components and reagents



**Sherry Hikita**  
Project Director, Cell Therapy R&D  
Novo Nordisk

#### 2.30 Roundtable Discussion: Implementing GMP-Compatible Practices into Preclinical iPSC Research

- Integrating GMP principles and processes into preclinical iPSC research workflows to enhance the development of treatments for solid tumors and ensure a smooth transition to clinical development
- Addressing the challenges of sourcing GMP-grade reagents and adapting research protocols to meet the specific needs of solid tumor treatments and aligning with large-scale manufacturing requirements for future clinical trials



**Annelise Bennaceur**  
Chief Scientific Officer  
iPSirius



**Ali Turhan**  
Chief Medical Officer  
IPSIRIUS

#### 2.30 Panel Discussion: Optimizing the iPSC Therapy Pipeline: Balancing Quality, Potency, & Cost

- Convening researchers, industry, and regulators for a comprehensive discussion on quality and potency in iPSC therapies
- Facilitating discussion on assays, quality control, and manufacturing for consistent, high-quality iPSC therapies



**Zhu Pirot**  
Director & Technical Leader, Platform  
CGT Analytical Development  
Bayer



### 3.00 Afternoon Refreshment Break & Networking

# Conference Day Two

## Thursday October 3, 2024

### Rethinking Translational & Strategic Priorities to Drive Next Steps Across the iPSC Industry



**Chris Barkey**  
Chief Executive Officer  
Swissfinity

#### 3.30 Exploring Partnership Models to Optimize Investment in iPSC-derived Cell Therapies

- Structuring deals to balance risks and rewards between industry and investors
- Understanding different partnership models to find the best fit for you
- Case studies of innovative partnership models to fund iPSC development

#### 4.00 Panel Discussion: Accelerating iPSC Therapy Development by Streamlining Processes & Mitigating Delays

- Minimizing the need for retesting when transitioning between research-grade and GMP-compliant materials and processes, reducing development timelines and associated costs
- Streamlining iPSC production workflows through automation, integration of advanced technologies, and process optimization to expedite development timelines and reduce overall costs



**Laura Koivusalo**  
Chief Executive Officer  
StemSight



**Chris Barkey**  
Chief Executive Officer  
Swissfinity

#### 4.30 Chair's Closing Remarks & End of Conference

“The quality of the event exceeded my expectations. Lately, it seems like everyone is throwing together a quick event whereby the results are sub-par. This was excellent. The networking, the talks and discussions, all excellent”

**Regional Sales Manager, Advanced Instruments, Past Partner**

“A really intimate event, highly specialized and knowledgeable expert speakers and participants. Multiple opportunities to engage in deep conversations with KOLs and prospective clients”

**Chief Business Officer, New York Blood Center, Past Partner**

# Partner With Us

## Forge New Collaborations & Develop Your Existing Relationships at the Must-Attend iPSC Event for 2024

A unique opportunity for 2024 has arisen with the **4th iPSC Drug Development & Manufacturing Summit**. For the first time in 3 years, we are uniting R&D and Process Development teams for 3 days of networking, knowledge sharing and cross-functional collaboration.

We will work with you to build a bespoke partnership package that allows you to make the essential connections with strategic leaders that align with your commercial objectives for 2024.



### Position Yourself as a Thought Leader

through podium presentations where you can demonstrate your subject expertise and specialized services that will make you stand out from the competition



### Tailor Your Offerings

with our new 2 track structure you can ensure your messaging is precise and being targeted at exactly the right biopharma decision makers



### Raise Brand Awareness

by building exposure to new clients and businesses both during the conference and the months leading up to it through our dynamic marketing collaborations



### Market Insights



are essential in this ever-changing space. Learn what solutions our biopharma audience are looking for and strategically prepare your offerings to align with these




### Network with Industry Pioneers

, whether it be brand-new indications or AI automation technologies, our audience are working on the cutting edge and looking to commercialize their iPSC therapies with your help

### SENIORITY OF ATTENDEES\*



### TYPES OF COMPANIES ATTENDING\*



\*Statistics Taken from iPSC-Derived Cell Therapies Summit Series

## GET INVOLVED



**Luke Kindness**

Partnerships Director

Tel: +1 617 455 4188

Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

## Program Partners



### PBS Biotech

PBS Biotech offers unique single-use bioreactors and contract process development services for the global cell therapy market. Our family of Vertical-Wheel bioreactors provides a gentle and scalable platform suitable for a variety of cell types. Leverage the expertise within our process development services team to help solve cell culture challenges and accelerate your path to commercialization. Contact us at [sales@pbsbiotech.com](mailto:sales@pbsbiotech.com) to learn more.

[www.pbsbiotech.com](http://www.pbsbiotech.com)



### Corning

Corning is vital to progress – in the industries we shape and in the world we share. We invent life-changing technologies using materials science. Our scientific and manufacturing expertise, boundless curiosity, and commitment to purposeful invention place us at the center of the way the world interacts, works, learns, and lives. Our sustained investment in research, development, and invention means we're always ready to solve the toughest challenges alongside our customers.

[www.corning.com](http://www.corning.com)

Eat Well, Live Well.



### Ajinomoto

Ajinomoto Health & Nutrition North America, Inc. is dedicated to transforming the landscape of healthcare through our StemFit and Purotein brands. Our commitment to excellence from bench to bedside is exemplified by our innovative products designed for the laboratory or GMP manufacturing of cell therapy products.

StemFit™ is a portfolio of products containing GMP, animal-origin free iPSC/ESC culture media, MSC culture media, and iPSC differentiation media. It offers a feeder-free, single passage method that eliminates the complexities of clumping and enables efficient expansion of iPS cells while maintaining genetic stability.

StemFit Purotein™, derived from the combination of 'Pure' and 'Protein', is a brand of recombinant proteins crucial for the differentiation of ES and iPS cells into various cell types such as liver, pancreas, heart, blood, and immune cells. These proteins are provided in a frozen liquid format, ready-to-use, and GMP upon request, eliminating the need for reconstitution and the possible introduction of contaminants.

At Ajinomoto, we leverage more than a century's worth of research and development in amino acid technology to contribute to the well-being of all human beings, our society, and our planet with "AminoScience" based on the corporate slogan "Eat Well, Live Well".

[www.ajitrade.com/stemfit](http://www.ajitrade.com/stemfit)



### Cellino

Cellino is building the leading platform to scale the production of autologous (personalized) regenerative medicines derived from induced pluripotent stem cells (iPSCs), which can be differentiated into a wide range of cell and tissue types. Current approaches to manufacturing iPSC-derived therapies are manually produced by hand and are not scalable to meet the needs of growing patient populations. Cellino's proprietary AI-driven platform automates iPSC manufacturing to make "Your cells, your cure" a reality for patients.

[www.cellinobio.com](http://www.cellinobio.com)

## GET INVOLVED



**Luke Kindness**

Partnerships Director

Tel: +1 617 455 4188

Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)



## RoslinCT

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization.

Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, Cell Banking and cGMP iPSC cell line development, gene editing, and differentiation.

With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company.

[www.roslinct.com](http://www.roslinct.com)

## Innovation Partners



## Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, life science, and Applikon bioreactor systems. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

[www.getinge.com/us](http://www.getinge.com/us)



## PeptiGrowth

PeptiGrowth Inc., a joint venture between Mitsubishi Corporation and PeptiDream Inc., is supporting the growth of regenerative medicine and cell therapy industry by offering a series of synthetic peptides that have equivalent functions to growth factors. Our peptides are chemically synthesized, completely animal component-free, and can achieve highly consistent quality, excellent scalability, and reasonable cost.

PeptiGrowth has launched 10 products as of May 2024 – HGF, TGF 1 inhibitor, BDNF, Noggin, BMP 4 or 7 selective inhibitor, VEGF, Wnt3a, EGF, and TPO peptides. We also have a plan to launch the impactful FGF2 peptide in September 2024.

[www.peptigrowth.com](http://www.peptigrowth.com)



## bit.bio

bit.bio is a synthetic biology company focused on human cells, advancing medicine and enabling curative treatments. The company does this by industrialising the manufacture of human cells and making them more accessible.

bit.bio's opti-ox deterministic cell programming technology enables conversion of induced pluripotent stem cells into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.

The company has a cell therapy pipeline, based on tx Cells, focused on serious diseases that lack effective treatments. The io Cells research cell product portfolio is opening up new possibilities in research and drug discovery.

[www.bit.bio.com](http://www.bit.bio.com)



## Accelerated Biosciences

Accelerated Biosciences is a regenerative medicine company with freedom-to-operate for the human Trophoblast Stem Cell (hTSC) platform with 50 patents granted. hTSCs are the earliest stem cells ethically sourced with both scale and immune privilege. We are providing GMP cells with a complete regulatory package to help cell and gene therapy developers accelerate their product time to market by 3 to 5 years. We have effectively de-risked the starting cell source decision for the regenerative medicine industry. We are available for partnering and licensing opportunities

[www.acceleratedbio.com](http://www.acceleratedbio.com)

# GET INVOLVED



**Luke Kindness**


Partnerships Director


Tel: +1 617 455 4188

Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

# Ready to Register?

## 3 Easy Ways to Book

 [www.ipsc-therapies-summit.com/take-part/register](http://www.ipsc-therapies-summit.com/take-part/register)

 Tel: +1 617 455 4188

 Email: [info@hansonwade.com](mailto:info@hansonwade.com)



**Discover** how innovative pioneers are driving forward iPSC research to make stem cell regenerative therapies a clinical reality.



**Uncover** how our expert speakers are overcoming major bottle necks to streamline and expand their manufacturing processes.



**Collaborate** across teams within your organization and with some of the leading thinkers in the iPSC field.

Drug Developer Pricing*	Register By Friday July 12	On the Door Price
Conference + 2 Workshops	\$3,347 <b>(Save \$850)</b>	\$4,197
Conference + 1 Workshop	\$2,898 <b>(Save \$700)</b>	\$3,598
Conference Only	\$2,449 <b>(Save \$550)</b>	\$2,999

Academic & Not-For-Profit Pricing**	Register By Friday July 12	On the Door Price
Conference + 2 Workshops	\$2,747 <b>(Save \$850)</b>	\$3,597
Conference + 1 Workshop	\$2,398 <b>(Save \$700)</b>	\$3,098
Conference Only	\$2,049 <b>(Save \$550)</b>	\$2,599

Solution Provider Pricing	Register By Friday July 12	On the Door Price
Conference + 2 Workshops	\$4,247 <b>(Save \$850)</b>	\$5,097
Conference + 1 Workshop	\$3,698 <b>(Save \$700)</b>	\$4,398
Conference Only	\$3,149 <b>(Save \$550)</b>	\$3,699

\*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

Do you work for a Not-for-Profit organization? Email us at [info@hansonwade.com](mailto:info@hansonwade.com) to inquire about attending

\*\*To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)


## Team Discounts\*\*\*

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5 + Attendees

\*\*\*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: [register@hansonwade.com](mailto:register@hansonwade.com)



## Venue

**Hilton Boston Logan Airport**  
One Hotel Drive, Boston, MA 02128, United States  
[www.hilton-boston-logan-airport.com](http://www.hilton-boston-logan-airport.com)

### TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom